

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product Code(s) DRE-C10830500

Product Name Bufexamac

Form Not applicable

NOTE [8] - No registration number is given for this substance because it is under the threshold in REACH Article 6(1) and not subject to the registration requirements according to REACH Title II

EC No (EU Index No) 219-451-1

CAS No 2438-72-4

Chemical name Bufexamac

Pure substance/mixture Substance

Formula C12H17NO3

Molecular weight 223.30

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended use Laboratory use

Uses advised against No information available

1.3. Details of the supplier of the safety data sheet

Supplier

LGC Limited Queens Road Teddington Middlesex TW11 0LY UNITED KINGDOM :+44 (0) 20 8943 7000 Fax :+44 (0) 20 8943 2767 eMail : gb@lgcstandards.com

Web: www.lgcstandards.com

For further information, please contact

E-mail address sds-request@lgcgroup.com

EGHS / EN Page 1/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

	_			
DRF.	.C1081	えのちのの _	Rufeyan	nac

1.4. Emergency telephone number

Emergency Telephone For Hazardous Materials or Dangerous Goods Incident

Spill, Leak, Fire Exposure, or Accident

Call CHEMTREC:

USA & Canada 1-800-424-9300 Rest of the world +1 703-741-5970

Emergency Telephone S4F /EC	24272/2009
Emergency Telephone - §45 - (EC	112
Europe	
Austria	No information available
Bulgaria	
Croatia	
Cyprus	
Czech Republic	
Denmark	
France	
Hungary	
Ireland	
Italy	
Lithuania	
Luxembourg	
Netherlands	
Norway	
Portugal	
Romania	
Slovakia	
Slovenia	
Spain	
Sweden	
Switzerland	

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

Skin sensitisation	Category 1 - (H317)
Effects on or via lactation	Yes - (H362)

2.2. Label elements

Contains Bufexamac

EGHS / EN Page 2/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac



Signal word Warning

Hazard statements

H317 - May cause an allergic skin reaction

H362 - May cause harm to breast-fed children

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use

P260 - Do not breathe dust/fume/gas/mist/vapours/spray

P263 - Avoid contact during pregnancy and while nursing

P280 - Wear protective gloves

P362 + P364 - Take off contaminated clothing and wash it before reuse

2.3. Other hazards

No information available.

This substance does not meet the PBT/vPvB criteria of REACH, annex XIII.

This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1)	EU - REACH (1907/2006) - Endocrine
	- Candidate List of Substances of Very	Disruptor Assessment List of
	High Concern (SVHC) for Authorisation	Substances
Bufexamac	-	-

SECTION 3: Composition/information on ingredients

3.1 Substances

Chemical name	Weight-%	REACH registration number		Classification according to Regulation (EC) No. 1272/2008 [CLP]	•	M-Factor	M-Factor (long-term)
Bufexamac 2438-72-4	100	-	219-451-1	Skin Sens. 1 (H317) Lact. (H362)	mint (GGE)		

EGHS / EN Page 3/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

If LD50/LC50 data is not available or does not correspond to the classification category, then the appropriate conversion value from CLP Annex I, Table 3.1.2, is used to calculate the acute toxicity estimate (ATEmix) for classifying a mixture based on its components

Chemical name	Oral LD50 mg/kg		Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4	Inhalation LC50 - 4 hour - gas - ppm
Bufexamac 2438-72-4	3370	No data available		No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59)

SECTION 4: First aid measures

4.1. Description of first aid measures

General advice Show this safety data sheet to the doctor in attendance.

Inhalation Remove to fresh air.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a doctor.

Skin contact Wash with soap and water. May cause an allergic skin reaction. In the case of skin irritation

or allergic reactions see a doctor.

Ingestion Rinse mouth.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms Itching. Rashes. Hives.

4.3. Indication of any immediate medical attention and special treatment needed

Note to doctors May cause sensitisation in susceptible persons. Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

EGHS / EN Page 4/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

surrounding environment.

Large Fire CAUTION: Use of water spray when fighting fire may be inefficient.

Unsuitable extinguishing mediaDo not scatter spilled material with high pressure water streams.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

Product is or contains a sensitiser. May cause sensitisation by skin contact.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Avoid contact with skin, eyes or clothing. Ensure adequate ventilation. Use personal

protective equipment as required. Evacuate personnel to safe areas. Keep people away

from and upwind of spill/leak.

6.2. Environmental precautions

Environmental precautions See Section 12 for additional Ecological Information.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning upTake up mechanically, placing in appropriate containers for disposal.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

EGHS / EN Page 5/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice. Avoid contact with Advice on safe handling

skin, eyes or clothing. Ensure adequate ventilation. In case of insufficient ventilation, wear suitable respiratory equipment. Do not eat, drink or smoke when using this product. Take off

contaminated clothing and wash it before reuse. Remove contaminated clothing and shoes.

Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Wash hands before breaks and after work. Wear suitable gloves and eye/face

protection. Wash hands before breaks and immediately after handling the product.

7.2. Conditions for safe storage, including any incompatibilities

Please refer to the manufacturer's certificate for specific storage and transport temperature **Storage Conditions**

conditions. Store only in the original receptacle unless other advice is given on the CoA.

Keep containers tightly closed in a dry, cool and well-ventilated place.

7.3. Specific end use(s)

Risk Management Methods (RMM) The information required is contained in this Safety Data Sheet.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

This product, as supplied, does not contain any hazardous materials with occupational **Exposure Limits**

exposure limits established by the region specific regulatory bodies.

Biological occupational exposure limits

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

Derived No Effect Level (DNEL) Predicted No Effect Concentration No information available. (PNEC)

No information available.

8.2. Exposure controls

Personal protective equipment

Eye/face protection Avoid contact with eyes. Wear safety glasses with side shields (or goggles).

EGHS / EN Page 6/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

Hand protection The protective gloves to be used must comply with the specifications of EC Directive

89/686/EEC and the related standard EN374. Wear suitable gloves.

	Gloves		
Duration of contact	PPE - Glove material	Glove thickness	Break through time
	Wear protective butyl		
	rubber gloves		

Skin and body protection Wear suitable protective clothing.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are

exceeded or irritation is experienced, ventilation and evacuation may be required.

General hygiene considerations Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this

product. Wash hands before breaks and after work. Wear suitable gloves and eye/face protection. Wash hands before breaks and immediately after handling the product.

Environmental exposure controls Do not allow into any sewer, on the ground or into any body of water.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical stateSolidAppearanceSolidColourwhite

OdourNo information available.Odour thresholdNo information available

<u>Property</u> <u>Values</u> <u>Remarks • Method</u>

Melting point / freezing point> 171 °CNone knownInitial boiling point and boiling rangeNo data availableNone knownFlammabilityNo data availableNone knownFlammability Limit in AirNone known

Upper flammability or explosive No data available

limits

Lower flammability or explosive No data available

limits

Flash pointNo data availableNone knownAutoignition temperatureNo data availableNone knownDecomposition temperatureNone known

pH No data available None known

pH (as aqueous solution)No data availableNo information availableKinematic viscosityNo data availableNone known

Dynamic viscosityNo data availableNone knownWater solubilityImmiscible in water >33.5 ug/mLNone known

EGHS / EN Page 7/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

Solubility(ies)DMSONone knownPartition coefficientNo data availableNone knownVapour pressureNo data availableNone knownRelative densityNo data availableNone known

Relative density

Bulk density

Liquid Density

No data available

No data available

No data available

Relative vapour density

No data available

None known

Particle characteristics

Particle Size No information available Particle Size Distribution No information available

9.2. Other information

Molecular weight 223.30 Molecular formula C12H17NO3

9.2.1. Information with regards to physical hazard classes Not applicable

9.2.2. Other safety characteristics No information available

SECTION 10: Stability and reactivity

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact None. **Sensitivity to static discharge** None.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions
None under normal processing.

10.4. Conditions to avoid

Conditions to avoid None known based on information supplied.

10.5. Incompatible materials

Incompatible materialsNone known based on information supplied.

Hazardous decomposition products None known based on information supplied.

EGHS / EN Page 8/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure

Product Information

Inhalation Specific test data for the substance or mixture is not available.

Eye contact Specific test data for the substance or mixture is not available.

Skin contact May cause sensitisation by skin contact. Specific test data for the substance or mixture is

not available. Repeated or prolonged skin contact may cause allergic reactions with

susceptible persons. (based on components).

Ingestion Specific test data for the substance or mixture is not available.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms Itching. Rashes. Hives.

Numerical measures of toxicity

Acute toxicity

Component Information

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Bufexamac	= 3370 mg/kg (Rat)	>5000 mg/kg (Rat)	

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritationBased on available data, the classification criteria are not met.

Serious eye damage/eye irritation No information available.

Respiratory or skin sensitisation May cause an allergic skin reaction.

EGHS / EN Page 9/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

Germ cell mutagenicity No information available.

Carcinogenicity No information available.

Reproductive toxicity Classification based on data available for ingredients. May cause harm to breast-fed

children.

STOT - single exposure No information available.

STOT - repeated exposureNo information available.

Aspiration hazard No information available.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity The environmental impact of this product has not been fully investigated.

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

EGHS / EN Page 10/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues/unused

products

Dispose of in accordance with local regulations. Dispose of waste in accordance with

environmental legislation.

Contaminated packaging Do not reuse empty containers.

SECTION 14: Transport information

IATA

14.1 UN number or ID numberNot regulated14.2 UN proper shipping nameNot regulated14.3 Transport hazard class(es)Not regulated14.4 Packing groupNot regulated14.5 Environmental hazardsNot applicable

14.6 Special precautions for user

Special Provisions No

None

IMDG

14.1 UN number or ID number
14.2 UN proper shipping name
14.3 Transport hazard class(es)
14.4 Packing group
14.5 Marine pollutant

Not regulated
Not regulated
Not regulated
Not applicable

14.6 Special precautions for user

Special Provisions None No information available

EGHS / EN Page 11/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Number 1 Revision date 14-Mar-2023

DRE-C10830500 - Bufexamac

14.7 Maritime transport in bulk No information available according to IMO instruments RID 14.1 UN number or ID number Not regulated 14.2 UN proper shipping name Not regulated 14.3 Transport hazard class(es) Not regulated 14.4 Packing group Not regulated 14.5 Environmental hazards Not applicable 14.6 Special precautions for user **Special Provisions** None ADR 14.1 UN number or ID number Not regulated

14.2 UN proper shipping name Not regulated 14.3 Transport hazard class(es) Not regulated 14.4 Packing group Not regulated 14.5 Environmental hazards Not applicable

14.6 Special precautions for user **Special Provisions**

None

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

National regulations

Germany

Water hazard class (WGK) non-hazardous to water (nwg)

Poland

SDS created according to the following Polish regulation: Act of February 25, 2011 on chemical substances and their mixtures (Journal of Laws of 2018, item 143, as amended). Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals Agency (EC) as amended. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labeling and packaging of substances and mixtures, as amended. Regulation of the Minister of Health of 10 August 2012 on the criteria and method of classifying chemical substances and their mixtures (Journal of Laws of 2012, item 1018). Regulation of the Minister of Health of 20 April 2012 on labeling packaging of hazardous substances and mixtures and some mixtures (Journal of Laws of 2012, item 445). Regulation of the Minister of Family, Labor and Social Policy of 12 June 2018 on the maximum allowable concentrations and intensities of factors harmful to health in the work environment (Journal of Laws of 2018, item 1286).

EGHS / EN Page 12/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

Announcement of the Minister of Economy, Labor and Social Policy of August 28, 2003 on the publication of the unified text of the Ordinance of the Minister of Labor and Social Policy on general health and safety at work regulations (Journal of Laws of 2003, No. 169, item 1650). Regulation of the Minister of Health of 30 December 2004 on occupational safety and health related to the presence of chemical agents in the workplace (Journal of Laws of 2005, No. 11, item 86). Act of December 14, 2012 on waste (Journal of Laws of 2013, item 21) Regulation of the Minister of Health of December 30, 2004 on occupational health and safety related to the presence of chemical agents in the workplace (Journal U. of 2005, No. 11, item 86). Waste Act of December 14, 2012 (Journal of Laws of 2013, item 21). Act of 13 June 2013 on the management of packaging and packaging waste, Journal of Laws 2013, item 888). Government statement of September 24, 2002 - European Agreement on the International Carriage of Dangerous Goods by Road (ADR) (Journal of Laws No. 194, item 1629 and Journal of Laws of 2003, No. 207, item 2013 and 2014).

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorisations and/or restrictions on use:

This product does not contain substances subject to authorisation (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

DIRECTIVE (EU) 2021/1187 on the marketing and use of explosives precursorsNot applicable

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

International Inventories

TSCA Complies under research and development exemption or is regulated by a different

government agency.

DSL/NDSL
EINECS/ELINCS
Contact supplier for inventory compliance status
Contact supplier for inventory compliance status
ENCS
Contact supplier for inventory compliance status
IECSC
Contact supplier for inventory compliance status
KECL
Contact supplier for inventory compliance status
Contact supplier for inventory compliance status
Contact supplier for inventory compliance status

EGHS / EN Page 13/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

AIIC

Contact supplier for inventory compliance status

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report

A Chemical Safety Assessment is not required for this substance

SECTION 16: Other information

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

H317 - May cause an allergic skin reaction

H362 - May cause harm to breast-fed children

Legend

SVHC: Substances of Very High Concern for Authorisation:

Legend Section 8: Exposure controls/personal protection

TWA TWA (time-weighted average) STEL STEL (Short Term Exposure Limit)

Ceiling Maximum limit value * Skin designation

Classification procedure	
Classification according to Regulation (EC) No. 1272/2008 [CLP]	Method Used
Acute oral toxicity	Calculation method
Acute dermal toxicity	Calculation method
Acute inhalation toxicity - gas	Calculation method
Acute inhalation toxicity - Vapour	Calculation method
Acute inhalation toxicity - dust/mist	Calculation method
Skin corrosion/irritation	Calculation method
Serious eye damage/eye irritation	Calculation method
Respiratory sensitisation	Calculation method
Skin sensitisation	Calculation method
Mutagenicity	Calculation method
Carcinogenicity	Calculation method
Reproductive toxicity	Calculation method

EGHS / EN Page 14/15



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 14-Mar-2023 Revision Number 1

DRE-C10830500 - Bufexamac

STOT - single exposure	Calculation method
STOT - repeated exposure	Calculation method
Acute aquatic toxicity	Calculation method
Chronic aquatic toxicity	Calculation method
Aspiration hazard	Calculation method
Ozone	Calculation method

Key literature references and sources for data used to compile the SDS

Agency for Toxic Substances and Disease Registry (ATSDR)

U.S. Environmental Protection Agency ChemView Database

European Food Safety Authority (EFSA)

EPA (Environmental Protection Agency)

Acute Exposure Guideline Level(s) (AEGL(s))

U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act

U.S. Environmental Protection Agency High Production Volume Chemicals

Food Research Journal

Hazardous Substance Database

International Uniform Chemical Information Database (IUCLID)

Japan GHS Classification

Australian National Industrial Chemicals Notification and Assessment Scheme (NICNAS)

NIOSH (National Institute for Occupational Safety and Health)

National Library of Medicine's ChemID Plus (NLM CIP)

National Library of Medicine's PubMed database (NLM PUBMED)

National Toxicology Program (NTP)

New Zealand's Chemical Classification and Information Database (CCID)

Organisation for Economic Co-operation and Development Environment, Health, and Safety Publications

Organisation for Economic Co-operation and Development High Production Volume Chemicals Programme

Organisation for Economic Co-operation and Development Screening Information Data Set

World Health Organization

Revision date 14-Mar-2023

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006 Disclaimer

The information in this safety data sheet (SDS) has been prepared with due care and is true and accurate to the best of our knowledge. The user must determine the suitability of the information for its particular purpose, ensure compliance with existing laws and regulations, and be aware that other or additional safety or performance considerations may arise when using, handling and/ or storing the material. The information in this SDS does not purport to be all inclusive or a guarantee as to the properties of the material supplied, and should be used only as a guide. LGC makes no warranties or representations as to the accuracy and completeness of the information contained herein, shall not be held responsible for the suitability of this information for the user's intended purposes or the consequences of such use, and shall not be liable for any damage or loss, howsoever arising, direct or otherwise.

End of Safety Data Sheet

EGHS / EN Page 15/15